Review




Structured Review

Human Protein Atlas lepr protein
Lepr Protein, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lepr protein/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
lepr protein - by Bioz Stars, 2026-05
90/100 stars

Images



Similar Products

91
Sino Biological human leptin receptor / lepr / cd295 protein
Human Leptin Receptor / Lepr / Cd295 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leptin receptor / lepr / cd295 protein/product/Sino Biological
Average 91 stars, based on 1 article reviews
human leptin receptor / lepr / cd295 protein - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

93
R&D Systems recombinant lepr fc fusion protein
Recombinant Lepr Fc Fusion Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant lepr fc fusion protein/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant lepr fc fusion protein - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Human Protein Atlas lepr protein
Lepr Protein, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lepr protein/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
lepr protein - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

91
Sino Biological recombinant lep r protein
Recombinant Lep R Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant lep r protein/product/Sino Biological
Average 91 stars, based on 1 article reviews
recombinant lep r protein - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

90
Thermo Fisher chicken lepr ecd fusion protein
Chicken Lepr Ecd Fusion Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chicken lepr ecd fusion protein/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
chicken lepr ecd fusion protein - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

91
Sino Biological human leptin receptor
Human Leptin Receptor, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human leptin receptor/product/Sino Biological
Average 91 stars, based on 1 article reviews
human leptin receptor - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier

94
R&D Systems sp 050 r d systems 7 lepr leptin receptor recombinant mouse leptin protein
Sp 050 R D Systems 7 Lepr Leptin Receptor Recombinant Mouse Leptin Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sp 050 r d systems 7 lepr leptin receptor recombinant mouse leptin protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
sp 050 r d systems 7 lepr leptin receptor recombinant mouse leptin protein - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

92
R&D Systems mouse recombinant leptin receptor lepr protein
EREG improved glucose tolerance in the absence of <t>leptin</t> in Lep ob mice and exhibited no effect in <t>LepR-deficient</t> Lepr db mice. ( A ) Body weight of Lep ob male mice in groups before and after treatment with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 26 days. Mice were on regular chow diet. Unpaired t -test, n = 7/group. ns, not significant. ( B , C ) Fat ( B ) and lean body ( C ) composition in same groups of mice at the end of the study was measured by Echo-MRI. Fat and lean mass are shown as % of the total weight (100%). ( D , E ) Glucose tolerance test (GTT) was performed in fasted Lep ob mice treated with PBS (Veh, open circles) or EREG (closed circles) ( n = 7 per group). GTT kinetics ( D ) and area under the curve (AUC) ( E ) are shown. Statistical significance was examined by ANOVA ( D ) and Student’s t -test ( E ). ( F ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test. ( G ) Weight before and after treatment of Lepr db male mice with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 4 weeks ( n = 6 per treatment). Mice were on regular chow. Unpaired Student’s t -test, n = 6/group. ( H , I ) Fat ( H ) and lean body ( I ) composition (% of total weight) in the same groups of mice at the end of the study were measured by Echo-MRI. ( J , K ) GTT kinetics ( J ) and AUC ( K ) were obtained from Lepr db mice treated with PBS (Veh, open circles) or EREG (closed circles). ANOVA ( J ) and Student’s t -test ( K ). ( L ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test.
Mouse Recombinant Leptin Receptor Lepr Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse recombinant leptin receptor lepr protein/product/R&D Systems
Average 92 stars, based on 1 article reviews
mouse recombinant leptin receptor lepr protein - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Cisbio Bioassays snap-tagged proteins (human vegfr2, human lepr
Development of SARS-CoV-2 spike protein/ACE2 TR-FRET binding assay (A) Principle of TR-FRET assay. (B) Scheme illustrating the TR-FRET-based RBD-d2 binding assay to SNAP-tagged ACE2 labeled with Lumi4-Tb. (C) Saturation binding curve of RBD-d2 to Lumi4-Tb-labeled SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 10). Non-specific binding was defined in the presence of an excess of non-labeled RBD (1 μM). (D and E) Association (D) and dissociation (E) kinetics of RBD-d2 binding (5 nM) to Lumi4-Tb-SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 4). Dissociation was initiated by adding unlabeled RBD (1 μM). (F) Binding of RBD-d2 (20 nM) to Lumi4-Tb-SNAP-ACE2 but not <t>Lumi4-Tb-SNAP-VEGFR2.</t> Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate. Insert: representative data of the expression level of Lumi4-Tb-labeled SNAP-ACE2 and SNAP-VEGFR2 assessed by Tb fluorescence measurement (620 nm). (G) Competition of RBD-d2 (5 nM) binding to Lumi4-Tb-SNAP-ACE2 by non-labeled RBD (1 μM), leptin, IL-6, MCP1, Gal3, insulin, EGF, VEGF (each at 100 nM). Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate; ∗∗∗∗p = 0.0001 by one-way ANOVA. “RBD-d2 Binding” in (F and G) corresponds to the TR-FRET ratio and is expressed as percent of basal (absence of RBD-d2). (H) RBD-d2 (20 nM) interaction with HEK293 cells expressing either SNAP-ACE2 or SNAP-LepR monitored by fluorescence microscopy. Scale bar, 10 μm. See also <xref ref-type=Figure S1 . " width="250" height="auto" />
Snap Tagged Proteins (Human Vegfr2, Human Lepr, supplied by Cisbio Bioassays, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/snap-tagged proteins (human vegfr2, human lepr/product/Cisbio Bioassays
Average 90 stars, based on 1 article reviews
snap-tagged proteins (human vegfr2, human lepr - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


EREG improved glucose tolerance in the absence of leptin in Lep ob mice and exhibited no effect in LepR-deficient Lepr db mice. ( A ) Body weight of Lep ob male mice in groups before and after treatment with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 26 days. Mice were on regular chow diet. Unpaired t -test, n = 7/group. ns, not significant. ( B , C ) Fat ( B ) and lean body ( C ) composition in same groups of mice at the end of the study was measured by Echo-MRI. Fat and lean mass are shown as % of the total weight (100%). ( D , E ) Glucose tolerance test (GTT) was performed in fasted Lep ob mice treated with PBS (Veh, open circles) or EREG (closed circles) ( n = 7 per group). GTT kinetics ( D ) and area under the curve (AUC) ( E ) are shown. Statistical significance was examined by ANOVA ( D ) and Student’s t -test ( E ). ( F ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test. ( G ) Weight before and after treatment of Lepr db male mice with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 4 weeks ( n = 6 per treatment). Mice were on regular chow. Unpaired Student’s t -test, n = 6/group. ( H , I ) Fat ( H ) and lean body ( I ) composition (% of total weight) in the same groups of mice at the end of the study were measured by Echo-MRI. ( J , K ) GTT kinetics ( J ) and AUC ( K ) were obtained from Lepr db mice treated with PBS (Veh, open circles) or EREG (closed circles). ANOVA ( J ) and Student’s t -test ( K ). ( L ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test.

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: EREG improved glucose tolerance in the absence of leptin in Lep ob mice and exhibited no effect in LepR-deficient Lepr db mice. ( A ) Body weight of Lep ob male mice in groups before and after treatment with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 26 days. Mice were on regular chow diet. Unpaired t -test, n = 7/group. ns, not significant. ( B , C ) Fat ( B ) and lean body ( C ) composition in same groups of mice at the end of the study was measured by Echo-MRI. Fat and lean mass are shown as % of the total weight (100%). ( D , E ) Glucose tolerance test (GTT) was performed in fasted Lep ob mice treated with PBS (Veh, open circles) or EREG (closed circles) ( n = 7 per group). GTT kinetics ( D ) and area under the curve (AUC) ( E ) are shown. Statistical significance was examined by ANOVA ( D ) and Student’s t -test ( E ). ( F ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test. ( G ) Weight before and after treatment of Lepr db male mice with Veh (PBS, white bar) or EREG (50 ng/g body weight (BW), black bar) for 4 weeks ( n = 6 per treatment). Mice were on regular chow. Unpaired Student’s t -test, n = 6/group. ( H , I ) Fat ( H ) and lean body ( I ) composition (% of total weight) in the same groups of mice at the end of the study were measured by Echo-MRI. ( J , K ) GTT kinetics ( J ) and AUC ( K ) were obtained from Lepr db mice treated with PBS (Veh, open circles) or EREG (closed circles). ANOVA ( J ) and Student’s t -test ( K ). ( L ) Insulin levels in plasma in both mouse groups were measured by ELISA. Unpaired student’s t -test.

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay

EREG regulated glucose uptake via binding with LepR in Lep ob mice. ( A ) EREG and insulin tolerance test in Lep ob mice ( n = 5 per group) treated with a single intraperitoneal injection of insulin (0.012 IU/g BW, triangle dashed line) or EREG (80 ng/g BW, closed circles. Asterisks, significant (* p < 0.05) compared to glucose levels before EREG treatment. # Hashtag, significant difference in glucose levels 30 min after treatment with EREG or insulin. Unpaired Student’s t -test. ( B ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student’s t -test, ns . ( C ) GTT kinetics were measured in Lep ob mice ( n = 5 per treatment) treated with a single injection of PBS (Veh, open circles) or EREG (closed circles). Student’s t -test. * p < 0.05 from comparison between control and EREG treated mice at each time point. ( D ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student’s t -test. ( E , F ). Immunoprecipitation of LepR was performed with anti-EREG antibody using homogenates from subcutaneous fat ( C ) and visceral fat ( D ). Fat tissue was isolated from non-treated Lep ob (Veh) as well as Lep ob mice 15 min after injection of EREG (50 ng/mL).

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: EREG regulated glucose uptake via binding with LepR in Lep ob mice. ( A ) EREG and insulin tolerance test in Lep ob mice ( n = 5 per group) treated with a single intraperitoneal injection of insulin (0.012 IU/g BW, triangle dashed line) or EREG (80 ng/g BW, closed circles. Asterisks, significant (* p < 0.05) compared to glucose levels before EREG treatment. # Hashtag, significant difference in glucose levels 30 min after treatment with EREG or insulin. Unpaired Student’s t -test. ( B ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student’s t -test, ns . ( C ) GTT kinetics were measured in Lep ob mice ( n = 5 per treatment) treated with a single injection of PBS (Veh, open circles) or EREG (closed circles). Student’s t -test. * p < 0.05 from comparison between control and EREG treated mice at each time point. ( D ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student’s t -test. ( E , F ). Immunoprecipitation of LepR was performed with anti-EREG antibody using homogenates from subcutaneous fat ( C ) and visceral fat ( D ). Fat tissue was isolated from non-treated Lep ob (Veh) as well as Lep ob mice 15 min after injection of EREG (50 ng/mL).

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Binding Assay, Injection, Comparison, Control, Immunoprecipitation, Isolation

EREG-stimulated glucose uptake was dependent on LepR but independent of EGFR. ( A , B ) Fluorescently-labelled (FD) glucose uptake was measured in stromal vascular fraction (SVF) cells isolated from visceral tissues of Lepr db ( A ) or Lep ob mice ( B ). Cells were treated with either Veh (PBS), mouse EREG (50 ng/mL), human insulin (Ins, 10 µg/mL), or mouse leptin (Lep, 200 ng/mL) for 80 min. For inhibition experiment, Lep ob SVF cells were pre-treated with EGFR inhibitor (EGFR-I, AST-1306, 10 µM) or vehicle (Veh, DMSO) for 40 min. Data are shown as a percentage of Veh-treated control (100%, n = 8 per treatment). Unpaired Student’s t -test. ( C – E ) FD-glucose uptake was measured in mouse 3T3-L3 preadipocytes. ( C ) Preadipocytes were treated with vehicle, human insulin (Ins, 10 µg/mL), and mouse EREG (50 ng/mL) for 30 min (mean ± SEM, n = 6, t -test). ( D ) Time-dependent uptake of FD-glucose in 3T3-L1 preadipocytes stimulated with human insulin (Ins, 10 µg/mL), mouse leptin (Lep, 200 ng/mL), and mouse EREG (50 ng/mL). Data are shown (mean ± SEM, n = 8, t -test) as % of glucose uptake compared to control cells at the same time point (Veh, 100%). ( E ) Concentration-dependent increase in FD-glucose uptake by 3T3-L1 preadipocytes stimulated with different concentrations of mouse EREG. Data are shown as a percentage of Veh-treated control (100%, n = 6 per concentration). * p < 0.05, significant differences compared to the vehicle group, one-way ANOVA). ( F ) NIH-3T3 preadipocytes were transiently transfected with pB- Glut4 -7myc-GFP and stimulated with vehicle, Ins (10 µg/mL), EREG (50 ng/mL) for 60 min. Data show representative fluorescent images of GFP-labeled GLUT4 selected from three independent experiments. 10× magnification. Yellow arrow shows GFP-labeled GLUT4 that was translocated to the cellular membrane. ( G ) Quantification of GFP was performed in adipocytes of similar size ( n = 10) in each group.

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: EREG-stimulated glucose uptake was dependent on LepR but independent of EGFR. ( A , B ) Fluorescently-labelled (FD) glucose uptake was measured in stromal vascular fraction (SVF) cells isolated from visceral tissues of Lepr db ( A ) or Lep ob mice ( B ). Cells were treated with either Veh (PBS), mouse EREG (50 ng/mL), human insulin (Ins, 10 µg/mL), or mouse leptin (Lep, 200 ng/mL) for 80 min. For inhibition experiment, Lep ob SVF cells were pre-treated with EGFR inhibitor (EGFR-I, AST-1306, 10 µM) or vehicle (Veh, DMSO) for 40 min. Data are shown as a percentage of Veh-treated control (100%, n = 8 per treatment). Unpaired Student’s t -test. ( C – E ) FD-glucose uptake was measured in mouse 3T3-L3 preadipocytes. ( C ) Preadipocytes were treated with vehicle, human insulin (Ins, 10 µg/mL), and mouse EREG (50 ng/mL) for 30 min (mean ± SEM, n = 6, t -test). ( D ) Time-dependent uptake of FD-glucose in 3T3-L1 preadipocytes stimulated with human insulin (Ins, 10 µg/mL), mouse leptin (Lep, 200 ng/mL), and mouse EREG (50 ng/mL). Data are shown (mean ± SEM, n = 8, t -test) as % of glucose uptake compared to control cells at the same time point (Veh, 100%). ( E ) Concentration-dependent increase in FD-glucose uptake by 3T3-L1 preadipocytes stimulated with different concentrations of mouse EREG. Data are shown as a percentage of Veh-treated control (100%, n = 6 per concentration). * p < 0.05, significant differences compared to the vehicle group, one-way ANOVA). ( F ) NIH-3T3 preadipocytes were transiently transfected with pB- Glut4 -7myc-GFP and stimulated with vehicle, Ins (10 µg/mL), EREG (50 ng/mL) for 60 min. Data show representative fluorescent images of GFP-labeled GLUT4 selected from three independent experiments. 10× magnification. Yellow arrow shows GFP-labeled GLUT4 that was translocated to the cellular membrane. ( G ) Quantification of GFP was performed in adipocytes of similar size ( n = 10) in each group.

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Isolation, Inhibition, Control, Concentration Assay, Transfection, Labeling, Membrane

EREG mediates glucose uptake via PI3K with transient activation of ERK. ( A ) FD-glucose uptake in 3T3-L3 preadipocytes treated with or without EREG (50 ng/mL) and in the presence of inhibitors for EGFR-I (AG1478, 10 µM), EGFR and ErbB2 (AST-1306 or CI-1033 10 µM), dual IR/IGF-1R inhibitor (BMS 536924, 1 µM), and SRC-I, AZM475271, 1 µM) for 30 min. Cells were starved for 90 min before stimulation. Dashed line shows glucose uptake in the presence of insulin (Ins, 10 µg/mL). ( B ) FD-glucose uptake was measured in mouse 3T3-L1 preadipocytes with or without EREG (50 ng/mL) and inhibitors of MEK1/2 and PI3K (MEK1/2-I, U0126 10 μM, and PI3K-I, wortmannin 200 nM). Data (mean ± SD, n = 6) are shown as a percentage of control (Veh 100%). Unpaired Student’s t -test. ( C ) 3T3-L1 preadipocytes were stimulated with EREG at different concentrations (0–100 ng/mL) for 5 or 15 min. The total and phosphorylated levels of AKT, STAT3, STAT5, and ERK were measured by Western blot in duplicates. Data are shown in a representative Western blot. ( D ) The kinetics of pERK expression was quantified based on the Western blots. pAKT, p-STAT3, and p-STAT5 analysis are described in . Pearson correlation analysis. ( E ) 3T3-L1 preadipocytes were stimulated with or without EREG or EGF (50 ng/mL, each) for 30 min in the presence and absence of EGFR inhibitor AST1306 (100 nM), and antibody against mouse LepR (Invitrogen, PA1-053, 10 μg/mL). For inhibition, cells were pre-treated 30 min before EREG and EGF stimulation. ( F ) FD-glucose uptake was measured in mouse 3T3-L3 preadipocytes pre-treated with either Veh (DMSO) or ERK inhibitors (U0126, SCH772984, or DEL 22379, each 10 µM in DMSO) for 40 min. Then, cells were treated with either Veh (PBS), mouse EREG (50 ng/mL), or mouse leptin (Lep, 200 ng/mL) for 80 min. Data are shown as a percentage of Veh-treated control (100%, n = 7 per group). Unpaired Student’s t -test. ns , not significant ( p > 0.05).

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: EREG mediates glucose uptake via PI3K with transient activation of ERK. ( A ) FD-glucose uptake in 3T3-L3 preadipocytes treated with or without EREG (50 ng/mL) and in the presence of inhibitors for EGFR-I (AG1478, 10 µM), EGFR and ErbB2 (AST-1306 or CI-1033 10 µM), dual IR/IGF-1R inhibitor (BMS 536924, 1 µM), and SRC-I, AZM475271, 1 µM) for 30 min. Cells were starved for 90 min before stimulation. Dashed line shows glucose uptake in the presence of insulin (Ins, 10 µg/mL). ( B ) FD-glucose uptake was measured in mouse 3T3-L1 preadipocytes with or without EREG (50 ng/mL) and inhibitors of MEK1/2 and PI3K (MEK1/2-I, U0126 10 μM, and PI3K-I, wortmannin 200 nM). Data (mean ± SD, n = 6) are shown as a percentage of control (Veh 100%). Unpaired Student’s t -test. ( C ) 3T3-L1 preadipocytes were stimulated with EREG at different concentrations (0–100 ng/mL) for 5 or 15 min. The total and phosphorylated levels of AKT, STAT3, STAT5, and ERK were measured by Western blot in duplicates. Data are shown in a representative Western blot. ( D ) The kinetics of pERK expression was quantified based on the Western blots. pAKT, p-STAT3, and p-STAT5 analysis are described in . Pearson correlation analysis. ( E ) 3T3-L1 preadipocytes were stimulated with or without EREG or EGF (50 ng/mL, each) for 30 min in the presence and absence of EGFR inhibitor AST1306 (100 nM), and antibody against mouse LepR (Invitrogen, PA1-053, 10 μg/mL). For inhibition, cells were pre-treated 30 min before EREG and EGF stimulation. ( F ) FD-glucose uptake was measured in mouse 3T3-L3 preadipocytes pre-treated with either Veh (DMSO) or ERK inhibitors (U0126, SCH772984, or DEL 22379, each 10 µM in DMSO) for 40 min. Then, cells were treated with either Veh (PBS), mouse EREG (50 ng/mL), or mouse leptin (Lep, 200 ng/mL) for 80 min. Data are shown as a percentage of Veh-treated control (100%, n = 7 per group). Unpaired Student’s t -test. ns , not significant ( p > 0.05).

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Activation Assay, Control, Western Blot, Expressing, Inhibition

Kinetics of the changes in LepR film thickness in the presence of leptin ( A ) or EREG ( B ). Film thickness was measured using QCM and quantified based on the binding kinetics to a gold sensor.

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: Kinetics of the changes in LepR film thickness in the presence of leptin ( A ) or EREG ( B ). Film thickness was measured using QCM and quantified based on the binding kinetics to a gold sensor.

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Binding Assay

Evolutionary analysis of EREG binding to LepR. ( A – E ) EREG docking to LepR. Evolutionary analysis of 175 open The dependence of EREG-mediated glucose uptake on the ERK phosphorylation cascade was examined using (1) a specific inhibitor of ERK1/2 SCH772984 , (2) an inhibitor of ERK dimerization DEL-22379 , and (3) a selective inhibitor of MEK1 and MEK2 U0126 . All inhibitors increased basal glucose uptake, which was further increased by leptin ( F). The inhibition of ERK1/2 and MEK1/2 as well as ERK dimerization prevented stimulatory effect of EREG on FD-glucose uptake but did not decrease it beyond the levels seen in the control cells. Although transient ERK phosphorylation occurred in response to EREG stimulation, this pathway was dispensable for glucose uptake and dependent on PI3K and may be other pathways ( B and ). ( F ) Hypothetic mechanism suggesting EREG as an alternative ligand for both EGFR and LepR. The canonic leptin/LepR response can induce JAK/STAT3 signaling and required the long form of LepR. The alternative binding of EREG to LepR can induce ERK and PI3K activation increasing GLUT4 translocation and glucose uptake, but not the other canonic effects of leptin, including the regulation of appetite and energy expenditure.

Journal: Cells

Article Title: Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity

doi: 10.3390/cells11030425

Figure Lengend Snippet: Evolutionary analysis of EREG binding to LepR. ( A – E ) EREG docking to LepR. Evolutionary analysis of 175 open The dependence of EREG-mediated glucose uptake on the ERK phosphorylation cascade was examined using (1) a specific inhibitor of ERK1/2 SCH772984 , (2) an inhibitor of ERK dimerization DEL-22379 , and (3) a selective inhibitor of MEK1 and MEK2 U0126 . All inhibitors increased basal glucose uptake, which was further increased by leptin ( F). The inhibition of ERK1/2 and MEK1/2 as well as ERK dimerization prevented stimulatory effect of EREG on FD-glucose uptake but did not decrease it beyond the levels seen in the control cells. Although transient ERK phosphorylation occurred in response to EREG stimulation, this pathway was dispensable for glucose uptake and dependent on PI3K and may be other pathways ( B and ). ( F ) Hypothetic mechanism suggesting EREG as an alternative ligand for both EGFR and LepR. The canonic leptin/LepR response can induce JAK/STAT3 signaling and required the long form of LepR. The alternative binding of EREG to LepR can induce ERK and PI3K activation increasing GLUT4 translocation and glucose uptake, but not the other canonic effects of leptin, including the regulation of appetite and energy expenditure.

Article Snippet: Mouse recombinant leptin receptor (LepR) protein (1.6 pM in PBS; R&D systems, 497-LR/CF) was added to establish a monolayer, followed by the addition of mouse leptin (1.6 fM in PBS; Crystal Chem, Elk Grove Village, IL, USA, 90030-B) or mouse EREG (1.6 fM).

Techniques: Binding Assay, Phospho-proteomics, Inhibition, Control, Activation Assay, Translocation Assay

Development of SARS-CoV-2 spike protein/ACE2 TR-FRET binding assay (A) Principle of TR-FRET assay. (B) Scheme illustrating the TR-FRET-based RBD-d2 binding assay to SNAP-tagged ACE2 labeled with Lumi4-Tb. (C) Saturation binding curve of RBD-d2 to Lumi4-Tb-labeled SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 10). Non-specific binding was defined in the presence of an excess of non-labeled RBD (1 μM). (D and E) Association (D) and dissociation (E) kinetics of RBD-d2 binding (5 nM) to Lumi4-Tb-SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 4). Dissociation was initiated by adding unlabeled RBD (1 μM). (F) Binding of RBD-d2 (20 nM) to Lumi4-Tb-SNAP-ACE2 but not Lumi4-Tb-SNAP-VEGFR2. Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate. Insert: representative data of the expression level of Lumi4-Tb-labeled SNAP-ACE2 and SNAP-VEGFR2 assessed by Tb fluorescence measurement (620 nm). (G) Competition of RBD-d2 (5 nM) binding to Lumi4-Tb-SNAP-ACE2 by non-labeled RBD (1 μM), leptin, IL-6, MCP1, Gal3, insulin, EGF, VEGF (each at 100 nM). Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate; ∗∗∗∗p = 0.0001 by one-way ANOVA. “RBD-d2 Binding” in (F and G) corresponds to the TR-FRET ratio and is expressed as percent of basal (absence of RBD-d2). (H) RBD-d2 (20 nM) interaction with HEK293 cells expressing either SNAP-ACE2 or SNAP-LepR monitored by fluorescence microscopy. Scale bar, 10 μm. See also <xref ref-type=Figure S1 . " width="100%" height="100%">

Journal: Cell Chemical Biology

Article Title: SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET

doi: 10.1016/j.chembiol.2021.06.008

Figure Lengend Snippet: Development of SARS-CoV-2 spike protein/ACE2 TR-FRET binding assay (A) Principle of TR-FRET assay. (B) Scheme illustrating the TR-FRET-based RBD-d2 binding assay to SNAP-tagged ACE2 labeled with Lumi4-Tb. (C) Saturation binding curve of RBD-d2 to Lumi4-Tb-labeled SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 10). Non-specific binding was defined in the presence of an excess of non-labeled RBD (1 μM). (D and E) Association (D) and dissociation (E) kinetics of RBD-d2 binding (5 nM) to Lumi4-Tb-SNAP-ACE2 expressed in HEK293 cells (representative curve, expressed as mean ± SD of triplicates; n = 4). Dissociation was initiated by adding unlabeled RBD (1 μM). (F) Binding of RBD-d2 (20 nM) to Lumi4-Tb-SNAP-ACE2 but not Lumi4-Tb-SNAP-VEGFR2. Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate. Insert: representative data of the expression level of Lumi4-Tb-labeled SNAP-ACE2 and SNAP-VEGFR2 assessed by Tb fluorescence measurement (620 nm). (G) Competition of RBD-d2 (5 nM) binding to Lumi4-Tb-SNAP-ACE2 by non-labeled RBD (1 μM), leptin, IL-6, MCP1, Gal3, insulin, EGF, VEGF (each at 100 nM). Data are expressed as mean ± SEM of three independent experiments, each performed in triplicate; ∗∗∗∗p = 0.0001 by one-way ANOVA. “RBD-d2 Binding” in (F and G) corresponds to the TR-FRET ratio and is expressed as percent of basal (absence of RBD-d2). (H) RBD-d2 (20 nM) interaction with HEK293 cells expressing either SNAP-ACE2 or SNAP-LepR monitored by fluorescence microscopy. Scale bar, 10 μm. See also Figure S1 .

Article Snippet: Plasmids encoding for SNAP-tagged proteins (human VEGFR2, human LepR) were obtained from Cisbio Bioassays (Codolet, France).

Techniques: Binding Assay, Labeling, Expressing, Fluorescence, Microscopy

Journal: Cell Chemical Biology

Article Title: SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET

doi: 10.1016/j.chembiol.2021.06.008

Figure Lengend Snippet:

Article Snippet: Plasmids encoding for SNAP-tagged proteins (human VEGFR2, human LepR) were obtained from Cisbio Bioassays (Codolet, France).

Techniques: Recombinant, Labeling, Transfection, Plasmid Preparation, Expressing, Software